Proposed mechanisms of neuroprotection for nicotine in Parkinson's disease [0.03%]
尼古丁在帕金森病中神经保护作用的机制研究
Namrata Kumari,Lauren E Cooke,Abby L Olsen
Namrata Kumari
Parkinson's disease (PD) is a neurological disorder that is characterized by the death of dopaminergic neurons in the substantia nigra. Despite extensive research, the exact cause of PD is unknown, and current treatment options are centered...
Diffuse putaminal degeneration without iron deposition in multiple system atrophy [0.03%]
多系统萎缩中苍白球变性但无铁沉积
Shin-Ichi Ueno,Taiji Tsunemi,Daisuke Taniguchi et al.
Shin-Ichi Ueno et al.
BackgroundMultiple system atrophy (MSA) is a progressive neurodegenerative disorder characterized by parkinsonism, cerebellar ataxia, and autonomic dysfunction. Putaminal hypointensities on T2 magnetic resonance imaging (MRI) are commonly o...
Discontinuation or acute unplanned cessation of oral dopaminergic medications in persons with Parkinson's disease: A practice review [0.03%]
帕金森病患者的多巴胺能药物撤药或急性意外停药实践回顾
Milan Beckers,Danny Hommel,Herma Lennaerts et al.
Milan Beckers et al.
Planned discontinuation or acute unplanned cessation of oral dopaminergic medications might result in a severe relapse of Parkinson's symptoms or, sporadically, in life-limiting withdrawal syndromes. Unplanned cessation may occur due to dys...
Parkinson's disease associated with LRRK2-R1441C mutation: Characterization and comparison with other LRRK2 mutations [0.03%]
LRRK2-R1441C突变帕金森病的临床特点及与其他LRRK2突变的比较
Rafi Hadad,Roy N Alcalay,Inna Senderova et al.
Rafi Hadad et al.
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene associate with familial and sporadic Parkinson's disease (PD). While various LRRK2 allelic variants have been studied, characteristics of R1441C carriers remain underexplored. We co...
Gaps in the Parkinson's disease therapeutic clinical pipeline: A focus on approaches targeting disease pathobiology [0.03%]
帕金森病治疗性临床药物研发中的缺口：针对疾病病理生物学的方法成为新焦点
Christos Koros,Brian Fiske,Leonidas Stefanis
Christos Koros
The understanding of the pathobiology of Parkinson's disease (PD) is evolving, based largely on genetic discoveries. Despite a rich pipeline of potential therapies addressing aspects of the underlying biology of the disease, there is curren...
Psychosis in early onset Parkinson's disease: A retrospective cohort study in southeast Minnesota [0.03%]
早发帕金森病精神病的病例队列研究
Mohamed Derhab,Aidan F Mullan,Pierpaolo Turcano et al.
Mohamed Derhab et al.
BackgroundEarly onset Parkinson's disease (EOPD), defined as Parkinson's disease (PD) diagnosed before age 50, often presents unique challenges compared to late-onset PD, particularly with regard to non-motor symptoms. Psychosis in EOPD is ...
Exploring the link between personality dimensions and non-motor fluctuations in Parkinson's disease [0.03%]
探究人格维度与帕金森病非运动波动之间的联系
Mathilde Boussac,Florent Faggianelli,Estelle Harroch et al.
Mathilde Boussac et al.
BackgroundParkinson's disease (PD) patients on dopaminergic drugs may experience non-motor fluctuations (NMFs) which are often heterogeneous and respond variably to treatments.ObjectiveWe evaluated if personality was associated to NMFs and ...
Knowledge and utilization of compensation strategies for Parkinson's disease in Dutch long-term care facilities: A survey among 130 healthcare professionals [0.03%]
荷兰长期护理机构中帕金森病代偿策略的知识和应用：一项针对130名卫生专业人员的调查研究
Ties J Gaveel,Anouk Tosserams,Maarten J Nijkrake et al.
Ties J Gaveel et al.
BackgroundCompensation strategies have been shown to improve functional mobility in people with Parkinson's disease (PD) who live independently. However, knowledge on its utilization in in long-term care (LTC) settings is unknown.ObjectiveT...
Depressive symptoms can negatively influence patient reported disease severity after subthalamic nucleus stimulation for Parkinson's disease [0.03%]
抑郁症状可对丘脑底核刺激治疗帕金森病后的患者报告的疾病严重程度产生负面影响
Christine Girges,Alexis de Roquemaurel,Nirosen Vijiaratnam et al.
Christine Girges et al.
BackgroundDepression can negatively influence an individual's perception of their disease. Although subthalamic nucleus deep brain stimulation (STN-DBS) is an effective treatment for Parkinson's disease (PD), some patients do not appreciate...
Understanding barriers and facilitators to participation in Parkinson's research in Black communities in the UK [0.03%]
理解英国黑人社区帕金森病研究参与的障碍和促进因素
Ivelina Dobreva,Sabrina Kalam,Moïse Roche et al.
Ivelina Dobreva et al.
People from Black backgrounds are underrepresented in Parkinson's research, despite evidence of higher disease burden and risk of dementia. Greater understanding of the factors influencing participation in Parkinson's research can improve r...